Public dataset
Recorded enzyme and transporter findings by polarity
Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.
What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
- Public rows
- 8,404
- Generated
- Schema version
- 1.3.0
Coverage
What this run contains
- Medicine–counterparty–role groups
- 8,404
- Source sentence records
- 20,358
- Asserted sentences
- 4,700
- Denied sentences
- 7,494
- Polarity not recorded
- 8,164
- Medicines represented
- 755
- Counterparties represented
- 36
- Corpus records considered
- 9,855
- All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
- inducer groups
- 617
- inhibitor groups
- 3,131
- not_recorded groups
- 3,074
- substrate groups
- 1,582
Method
How the rows were made
- A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
- A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
- Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
- Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
- The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.
Limits
Read these before using a row
- A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
- This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
- ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
- A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
- 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
- Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
- 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
- 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
- The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
- The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
- A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
- Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.
Provenance
Source examples
Abacavir · CYP3A4 inhibitor
2 asserted · 2 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.
Abacavir · BCRP substrate
0 asserted · 4 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.
Abacavir · CYP2C9 not_recorded
0 asserted · 0 denied · 2 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).
Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| medicineName | string | Recorded medicine name; not normalized for display style. |
| counterparty | string | The exact recorded counterparty spelling. |
| role | string | SUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role. |
| assertedCount | number | Sentence records whose polarity is ASSERTED. |
| deniedCount | number | Sentence records whose polarity is NEGATED. |
| polarityNotRecordedCount | number | Sentence records for which the parser did not settle assertion or denial. |
| sentences | sentence[] | Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated. |
Reader
Search and filter the rows
Showing 1,441–1,450 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1441
- Medicine slug
- cladribine
- Medicine name
- Cladribine
- Enzyme or transporter
- P-GLYCOPROTEIN
- Role
- SUBSTRATE
- Asserted sentences
- 2
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:f1d650a5-4205-720b-f39b-4213277b6612 (opens source in a new tab)
Cladribine label
Version not recorded · Effective date not recorded
Transporter Systems: Cladribine is a substrate of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3).
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:f1d650a5-4205-720b-f39b-4213277b6612 (opens source in a new tab)
Cladribine label
Version not recorded · Effective date not recorded
Transporter Systems: Cladribine is a substrate of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3).
Projected row 1442
- Medicine slug
- cladribine
- Medicine name
- Cladribine
- Enzyme or transporter
- P-GP
- Role
- SUBSTRATE
- Asserted sentences
- 2
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:f1d650a5-4205-720b-f39b-4213277b6612 (opens source in a new tab)
Cladribine label
Version not recorded · Effective date not recorded
Transporter Systems: Cladribine is a substrate of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3).
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:f1d650a5-4205-720b-f39b-4213277b6612 (opens source in a new tab)
Cladribine label
Version not recorded · Effective date not recorded
Transporter Systems: Cladribine is a substrate of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3).
Projected row 1443
- Medicine slug
- clobazam
- Medicine name
- Clobazam
- Enzyme or transporter
- CYP1A2
- Role
- INDUCER
- Asserted sentences
- 0
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Clobazam and N-desmethylclobazam did not significantly increase CYP1A2 or CYP2C19 activities, but did induce CYP3A4 activity in a concentration-dependent manner.
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Clobazam and N-desmethylclobazam did not significantly increase CYP1A2 or CYP2C19 activities, but did induce CYP3A4 activity in a concentration-dependent manner.
Projected row 1444
- Medicine slug
- clobazam
- Medicine name
- Clobazam
- Enzyme or transporter
- CYP1A2
- Role
- INHIBITOR
- Asserted sentences
- 0
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Drug Interaction Studies In vitro studies: Clobazam did not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A4, UGT1A6, or UGT2B4 in vitro.
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Drug Interaction Studies In vitro studies: Clobazam did not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A4, UGT1A6, or UGT2B4 in vitro.
Projected row 1445
- Medicine slug
- clobazam
- Medicine name
- Clobazam
- Enzyme or transporter
- CYP1A2
- Role
- SUBSTRATE
- Asserted sentences
- 2
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
In vivo studies: Potential for Clobazam to Affect Other Drugs The effect of repeated 40 mg once-daily doses of clobazam on the pharmacokinetic profiles of single-dose dextromethorphan (CYP2D6 substrate), midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), and tolbutamide (CYP2C9 substrate), was studied when these probe substrates were given as a drug cocktail (N=18).
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
In vivo studies: Potential for Clobazam to Affect Other Drugs The effect of repeated 40 mg once-daily doses of clobazam on the pharmacokinetic profiles of single-dose dextromethorphan (CYP2D6 substrate), midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), and tolbutamide (CYP2C9 substrate), was studied when these probe substrates were given as a drug cocktail (N=18).
Projected row 1446
- Medicine slug
- clobazam
- Medicine name
- Clobazam
- Enzyme or transporter
- CYP2B6
- Role
- INDUCER
- Asserted sentences
- 0
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The potential for clobazam or N-desmethylclobazam to induce CYP2B6 and CYP2C8 has not been evaluated.
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The potential for clobazam or N-desmethylclobazam to induce CYP2B6 and CYP2C8 has not been evaluated.
Projected row 1447
- Medicine slug
- clobazam
- Medicine name
- Clobazam
- Enzyme or transporter
- CYP2B6
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The major metabolic pathway of clobazam involves N-demethylation, primarily by CYP3A4 and to a lesser extent by CYP2C19 and CYP2B6.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The major metabolic pathway of clobazam involves N-demethylation, primarily by CYP3A4 and to a lesser extent by CYP2C19 and CYP2B6.
Projected row 1448
- Medicine slug
- clobazam
- Medicine name
- Clobazam
- Enzyme or transporter
- CYP2C19
- Role
- INDUCER
- Asserted sentences
- 0
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Clobazam and N-desmethylclobazam did not significantly increase CYP1A2 or CYP2C19 activities, but did induce CYP3A4 activity in a concentration-dependent manner.
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Clobazam and N-desmethylclobazam did not significantly increase CYP1A2 or CYP2C19 activities, but did induce CYP3A4 activity in a concentration-dependent manner.
Projected row 1449
- Medicine slug
- clobazam
- Medicine name
- Clobazam
- Enzyme or transporter
- CYP2C19
- Role
- INHIBITOR
- Asserted sentences
- 4
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Strong (e.g., fluconazole, fluvoxamine, ticlopidine) and moderate (e.g., omeprazole) inhibitors of CYP2C19 may result in up to a 5-fold increase in exposure to N-desmethylclobazam, the active metabolite of clobazam, based on extrapolation from pharmacogenomic data [see Clinical Pharmacology ( 12.5 )].
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Dosage adjustment of clobazam may be necessary when co-administered with strong or moderate CYP2C19 inhibitors [see Drug Interactions ( 7.4 )].
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Strong (e.g., fluconazole, fluvoxamine, ticlopidine) and moderate (e.g., omeprazole) inhibitors of CYP2C19 may result in up to a 5-fold increase in exposure to N-desmethylclobazam, the active metabolite of clobazam, based on extrapolation from pharmacogenomic data [see Clinical Pharmacology ( 12.5 )].
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Dosage adjustment of clobazam may be necessary when co-administered with strong or moderate CYP2C19 inhibitors [see Drug Interactions ( 7.4 )].
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Drug Interaction Studies In vitro studies: Clobazam did not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A4, UGT1A6, or UGT2B4 in vitro.
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Drug Interaction Studies In vitro studies: Clobazam did not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A4, UGT1A6, or UGT2B4 in vitro.
Projected row 1450
- Medicine slug
- clobazam
- Medicine name
- Clobazam
- Enzyme or transporter
- CYP2C19
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 15
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The major metabolic pathway of clobazam involves N-demethylation, primarily by CYP3A4 and to a lesser extent by CYP2C19 and CYP2B6.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
N-desmethylclobazam is extensively metabolized, mainly by CYP2C19.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The polymorphic CYP2C19 is the major contributor to the metabolism of the pharmacologically active N-desmethylclobazam [see Clinical Pharmacology ( 12.5 )] .
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
In CYP2C19 poor metabolizers, levels of N-desmethylclobazam were 5-fold higher in plasma and 2- to 3-fold higher in the urine than in CYP2C19 extensive metabolizers.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The effects of concomitant antiepileptic drugs that are CYP3A4 inducers (phenobarbital, phenytoin, and carbamazepine), CYP2C19 inducers (valproic acid, phenobarbital, phenytoin, and carbamazepine), and CYP2C19 inhibitors (felbamate and oxcarbazepine) were evaluated using data from clinical trials.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The major metabolic pathway of clobazam involves N-demethylation, primarily by CYP3A4 and to a lesser extent by CYP2C19 and CYP2B6.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
N-desmethylclobazam is extensively metabolized, mainly by CYP2C19.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The polymorphic CYP2C19 is the major contributor to the metabolism of the pharmacologically active N-desmethylclobazam [see Clinical Pharmacology ( 12.5 )] .
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
In CYP2C19 poor metabolizers, levels of N-desmethylclobazam were 5-fold higher in plasma and 2- to 3-fold higher in the urine than in CYP2C19 extensive metabolizers.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The effects of concomitant antiepileptic drugs that are CYP3A4 inducers (phenobarbital, phenytoin, and carbamazepine), CYP2C19 inducers (valproic acid, phenobarbital, phenytoin, and carbamazepine), and CYP2C19 inhibitors (felbamate and oxcarbazepine) were evaluated using data from clinical trials.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Alcohol may have additive CNS depressant effects when taken with clobazam [see Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.2 )]. 12.5 Pharmacogenomics The polymorphic CYP2C19 is the main enzyme that metabolizes the pharmacologically active N-desmethylclobazam.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Compared to CYP2C19 extensive metabolizers, N-desmethylclobazam AUC and C max are approximately 3 to 5 times higher in poor metabolizers (e.g., subjects with *2/*2 genotype) and 2 times higher in intermediate metabolizers (e.g., subjects with *1/*2 genotype).
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The prevalence of CYP2C19 poor metabolism differs depending on racial/ethnic background.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
Dosage in patients who are known CYP2C19 poor metabolizers may need to be adjusted [see Dosage and Administration ( 2.5 )].
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)
Clobazam label
Version not recorded · Effective date not recorded
The systemic exposure of clobazam is similar for both CYP2C19 poor and extensive metabolizers.
Access
Query or download the projection
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=1440Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- role
- Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
- counterparty
- Exact recorded counterparty spelling.
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.